BlossomHill net loss widens 79.35% to $23.8 million in Q2 FY26; R&D expenses rise 70.78% to $21.4 million

Bitget2026/09/18 11:01

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

BlossomHill posted a Q2 2026 net loss of $23.8 million, widening from $13.2 million a year earlier.
R&D expense climbed 70.8% to $21.4 million, while G&A more than doubled to $3.3 million.
Cash and cash equivalents were $95.4 million at June 30; an August IPO raised $168.3 million in gross proceeds.
R&D rose primarily on higher SOLARA trial costs, BH-501284 IND-enabling work, and higher personnel, facilities and overhead.
FDA Fast Track for BH-30643; Q4 end-of-Phase 1 meeting planned, with first patient dosing in a pivotal Phase 2 expected in Q1 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Blossomhill Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609180700PRIMZONEFULLFEED9829323) on September 18, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

BlossomHill net loss widens 79.35% to $23.8 million in Q2 FY26; R&D expenses rise 70.78% to $21.4 million

You may also like

Crypto prices